stockrowTrulieve Cannabis Corp.
TRLV Healthcare Drug Manufacturers Specialty & Generic
Trulieve Cannabis Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- −20.1%
- EPS
- −2,391.1%
- Free cash flow
- +24.5%
- Total debt
- −37.0%
Quarter to September 2026, against a year earlier
Follow TRLV
Alert me
Trulieve Cannabis Corp. (TRLV) Shares outstanding
Trulieve Cannabis Corp.'s shares outstanding at the end of fiscal 2025 was $191.3M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $200.6M. Over the past ten years it has ranged from $118.3M (fiscal 2020) to $191.3M (fiscal 2025) — the current reading is the highest in ten years. Trulieve Cannabis Corp. ranks 17th of 81 Drug Manufacturers Specialty & Generic companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $191.3M | 0.70% |
| FY2024 | $190.0M | 0.54% |
| FY2023 | $189.0M | 0.52% |
| FY2022 | $188.0M | 28.10% |
| FY2021 | $146.8M | 24.03% |
| FY2020 | $118.3M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $200.6M | 4.10% |
| Jun 2026 | $192.7M | (2.55%) |
| Mar 2026 | $197.8M | 3.37% |
| Dec 2025 | $191.3M | 0.02% |
| 19 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ALVO Alvotech compare | $295.0M |
| BCRX BioCryst Pharmaceuticals, Inc. compare | $267.6M |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | $214.3M |
| TRLV Trulieve Cannabis Corp. | $200.6M |
| XERS Xeris Biopharma Holdings, Inc. compare | $189.9M |
| PRGO Perrigo Company plc compare | $139.4M |
| PBH Prestige Consumer Healthcare Inc. compare | $47.6M |
| ANIP ANI Pharmaceuticals, Inc. compare | $21.7M |
| RGC Regencell Bioscience Holdings Limited compare | — |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on TRLV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement